9 September 2026
Aspen has abandoned local lenacapavir production, citing no guaranteed demand, and is backing Merck's alimatravir pill instead.
3 September 2026
Lenacapavir HIV prevention could accelerate South Africa’s epidemic control, but severe supply constraints are limiting the rollout.
6 August 2026
The reduction in PEPFAR funding has led to a decrease in HIV services worldwide and put access to treatment and prevention programmes at risk.
5 August 2026
Lenacapavir production moves closer in SA as three local pharmaceutical manufacturers are shortlisted to produce the HIV-prevention injection.
3 August 2026
Older adults with HIV will nearly double by 2040. South Africa faces one of the sharpest rises, straining health systems.
28 July 2026
Global HIV funding cuts pushed financing to a 20-year low in 2025, threatening prevention, research and the goal of ending AIDS by 2030.
27 July 2026
Aspen HIV prevention pill licensing deal positions the SA manufacturer to supply lower-cost monthly PrEP across key African markets.
29 June 2026
Lenacapavir HIV prevention offers twice-yearly PrEP, but trust, access, stigma and continued engagement will determine its impact.
25 June 2026
Global HIV treatment gap leaves 8.8 million people without therapy as funding cuts weaken testing, prevention and community-led services.
12 June 2026
The Lenacapavir PrEP Rollout offers six-month HIV protection, but aid cuts and clinic access gaps raise concerns for high-risk groups.
10 June 2026
The lenacapavir HIV Prevention Injection rollout begins in SA, but activists warn that limited supply from Gilead could blunt the impact.
26 March 2026
Lenacapavir manufacturing in SA aims to strengthen supply chains and provide critical HIV prevention solutions.